Antengene's Exciting Development with ATG-022
Antengene Corporation Limited, a prominent name in innovative biotechnologies, is making significant strides in the field of oncology. Recently, the company celebrated a major milestone with the approval of its investigational new drug (IND) application by China's National Medical Products Administration (NMPA) for their Phase Ib/II study, focusing on the innovative treatment ATG-022. This therapy is poised to be combined with KEYTRUDA® (pembrolizumab) and chemotherapy, marking a significant advancement in the fight against cancer.
Understanding the Study: What Is CLINCH-2?
The study, known as CLINCH-2, will be spearheaded by Professor Lin Shen at Beijing Cancer Hospital. It aims to explore the efficiency of two distinct combination treatment regimens targeting patients afflicted by unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma. This patient group has been categorized as CLDN18.2-positive, HER2-negative, and PD-L1-positive (CPS?1).
The two regimens being evaluated are ATG-022 combined with pembrolizumab, and the same combination further augmented with the CAPOX chemotherapy regimen. This comprehensive study's primary objective is to ascertain the safety and tolerability of these combinations, while the secondary aims delve into their preliminary antitumor activity, the immunogenic properties of ATG-022, and its pharmacokinetic profile.
Clinical Insights from the CLINCH Study
Recent data from Antengene indicated promising results from the earlier Phase I/II CLINCH study of ATG-022, which focuses on advanced gastric cancer. This pivotal information was shared at the European Society for Medical Oncology Congress 2025 (ESMO 2025). The results pinpointed significant safety and efficacy patterns, showcasing that in the 1.8 mg/kg dose group, a mere 18.2% experienced grade 3 or higher treatment-related adverse events.
Additionally, researchers noted no instances of ocular toxicity or interstitial lung disease, emphasizing ATG-022's relatively low associated peripheral neuropathy incidence. Importantly, both the efficacious doses of 1.8 mg/kg and 2.4 mg/kg illustrated an objective response rate (ORR) of 40%. This robust performance reinforces ATG-022's applicability alongside pembrolizumab and chemotherapy in initial treatment settings.
What makes this study particularly noteworthy is that antitumor activities have been observed across varying levels of CLDN18.2 expression. This versatility hints at a broader eligibility spectrum for patients compared to existing CLDN18.2 targeting treatments.
The Future of ATG-022 and Antengene
Antengene is committed to propelling both the ongoing CLINCH study and the newly approved CLINCH-2. They plan to present updated findings at upcoming medical conferences, further underscoring ATG-022's clinical promise. The anticipation surrounding these developments illustrates the company's dedication to its revolutionary therapies and underscores their vital role in addressing critical unmet medical needs.
The Significance of CLDN18.2-targeted Treatments
ATG-022 stands out due to its targeted action against the CLDN18.2 protein, showcasing remarkable affinity and rapid cellular internalization. This ADC utilizes a VC-MMAE linker-payload, achieving profound effectiveness across a spectrum of tumors exhibiting various CLDN18.2 expression levels. Additionally, ATG-022 has earned two Orphan Drug designations by the FDA for treating gastric and pancreatic cancers, emphasizing its potential in the clinical landscape.
The therapy has also received Breakthrough Therapy Designation from the NMPA in China targeting specific gastric cancer categories, highlighting its importance in treating patients who have previously undergone multiple therapies. This acknowledgment showcases Antengene's commitment to innovative and next-generation cancer treatments.
About Antengene Corporation
Antengene Corporation Limited is a globally recognized R&D-driven biotech company. It strives to develop first-in-class and best-in-class therapeutics for conditions with significant unmet medical requirements. Antengene's diverse pipeline encompasses a range of researched and commercially viable programs. Their lead project, XPOVIO® (selinexor), has already gained approvals across several markets and has been incorporated into national insurance schemes in multiple regions.
Ultimately, as Antengene continues to evolve and expand its influence, the future looks bright for both the company and those reliant on advanced therapeutic solutions in the arena of cancer treatment.
Frequently Asked Questions
What is ATG-022?
ATG-022 is an antibody-drug conjugate targeting the CLDN18.2 protein, specifically designed for treating certain types of cancers.
What does the CLINCH-2 study aim to achieve?
The CLINCH-2 study seeks to evaluate the safety and effectiveness of combining ATG-022 with KEYTRUDA® and chemotherapy for treating gastric and gastroesophageal cancers.
Who is leading the CLINCH-2 study?
Professor Lin Shen is the principal investigator, overseeing the trials conducted at Beijing Cancer Hospital.
Is ATG-022 currently available for patients?
ATG-022 remains in clinical trials, and results from these studies will determine its future availability for patients.
What milestones has Antengene achieved?
Antengene has received 32 IND approvals and has introduced its lead asset into multiple international markets, reflecting its growth and commitment to innovative therapies.
